Oncology News | pharmaphorum

News

Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.

News

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.

News

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

Owkin has partnered 20 healthcare institutions on a patient data mining project, ATLANTIS, across oncology, immunology/inflammation, and neurology.

News

Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.

News

Eikon has added to its already copious cash reserves with a $351m round for its expanding pipeline of cancer therapies.